Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
June 2012
Features
Part D Changes for 2013 Will Put Pressure on P&T Committees
Drug Utilization Reviews and Medication Therapy Management Programs Under the Gun
Medicare wants to improve its drug program’s effectiveness, reduce costs, and
increase its oversight of formulary policies and prescribing, especially for opioids.
Stephen Barlas
Health Care and Law
Policies and Procedures
Enhancing Pharmacy Practice and Limiting Risk
P&T committee members, many of whom are not pharmacists, must be able to understand their organization’s P&Ps in order to minimize patient injury and avoid legal land mines.
James O’Donnell, PharmD, MS; and F. Randy Vogenberg, RPh, PhD
Management of Urinary Incontinence
Almost 10 million people in the U.S., many of them elderly, have various forms of this troubling condition. The types and causes of, risk factors for, and physiology of urinary incontinence, as well as conservative and pharmacological treatments, are discussed.
George A. DeMaagd, PharmD, BCPS; and Timothy C. Davenport, MD
Meeting Highlights
47th European Association for the Study of the Liver (EASL)/The International Liver Conference
Topics include interferon-free therapies, pegylated interferon lambda-1a, and
boceprevir (Victrelis) for the treatment of hepatitis C virus infection.
Walter Alexander
Meeting Highlights
American Academy of Dermatology
Sessions included therapies for psoriasis, acne, nail fungus, and superficial skin cancers.
Peter Sonnenreich, MA
Departments
Medication Errors
Actively Caring for the Safety of Patients
Overcoming Bystander Apathy
Eliminating bystander apathy requires active participation.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
FDA to Reassess Policies on Unsolicited Requests for Off-Label Information
Differentiating ‘Scientific Exchange’ From ‘Promotion’ Is Complicated
Will the FDA ease restrictions on disseminating unsolicited requests for off-label
information?
Stephen Barlas
New Drugs/Drug News/New Medical Devices
FDA approvals, drug indications, and updates
Pharmaceutical Approval Update
Florbetapir F18 (Amyvid) dye for detecting plaques in Alzheimer’s disease; avanafil (Stendra) for erectile dysfunction; and peginesatide injection (Omontys) for anemia in patients with chronic kidney disease
Marvin M. Goldenberg, PhD, RPh, MS
